EN | UA
EN | UA

Help Support

Back

Omalizumab is effective to treat severe chronic rhinosinusitis with polyposis

Rhinosinusitis Rhinosinusitis
Rhinosinusitis Rhinosinusitis

What's new?

In people having chronic rhinosinusitis with nasal polyps, omalizumab reduces size of polyp, improves smelling ability, and elevates the quality of life.

A study revealed the positive impact of omalizumab as add-on therapy in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP). Nadine Gunder et al. aimed to assess effectiveness of omalizumab for management of severe CRSwNP.

A total of 11 adult patients suffering from CRSwNP and poor response to intranasal corticosteroids were recruited. Based on total Immunoglobulin E (IgE) and body weight, participants were given 150-450 mg omalizumab every 4 weeks. The period for observation was sixteen weeks.

Examination of alterations in nasal polyp score (NPS) from baseline to week sixteen was done. Utilizing the Sino-Nasal Outcome Test-20 (SNOT-20) score, the influence on quality of life was done while using the Sniffin' Sticks, the influence on olfaction was assessed. Notably, 10 of 11 volunteers accomplished visit 4 (V4, 5th omalizumab injection) during observation period.

At visit 4, a profound decrease in NPS and an improvement in quality of life and olfaction were seen, as shown in Table 1:

During 16 weeks of use, only 1 patient exhibited no response to omalizumab.  Hence, the monoclonal antibody omalizumab appears to be a promising add-on therapy to treat severe CRSwNP.

Source:

Thieme

Article:

Efficacy of omalizumab in the treatment of severe chronic rhinosinusitis with polyposis (CRSwNP)

Authors:

Nadine Gunder et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: